In the midst of the COVID-19 pandemic, healthcare workers faced a disproportionately high risk of infection, often despite stringent personal protective measures. The search for affordable, safe, and readily available prophylactic agents became a global priority. One repurposed drug that drew attention was bromhexine hydrochloride, a well-known mucolytic with a surprising antiviral twist: its ability to inhibit TMPRSS2, a host cell protease essential for SARS-CoV-2 entry. The open-label randomized trial led by Mikhaylov et al. specifically investigated whether bromhexine could shield medical personnel from COVID-19, offering a glimmer of hope for frontline protection.
The Urgent Need for Prophylaxis in Healthcare Settings
Throughout the pandemic, medical personnel bore a heavy burden. Prolonged exposure to infected patients, shortages of N95 respirators, and the emergence of highly transmissible variants all contributed to elevated infection rates among hospital staff. In many regions, healthcare worker absenteeism due to illness or quarantine further strained already overstretched systems. While vaccines eventually provided long-term immunity, their deployment took time, and breakthrough infections remained a concern. Thus, pre-exposure prophylaxis (PrEP) remained an attractive complementary strategy, especially in low-resource settings where vaccine access lagged.
Pharmacological prophylaxis was not a new concept; however, identifying a suitable agent required a delicate balance of safety, tolerability, and efficacy. Candidates had to be non-toxic enough for healthy individuals to take regularly, yet potent enough to thwart viral invasion. Hydroxychloroquine, ivermectin, and other drugs were tested with mixed or disappointing results. Bromhexine, in contrast, had a decades-long safety record as an over-the-counter expectorant, making it an appealing candidate for repurposing.
Bromhexine: From Mucolytic to Antiviral Candidate
Bromhexine hydrochloride is best known as a secretolytic agent that thins mucus, widely used to treat respiratory conditions like chronic bronchitis. Its active metabolite, ambroxol, shares these properties. The drug's antiviral potential emerged during the SARS-CoV-1 outbreak of the early 2000s, when researchers discovered that bromhexine and ambroxol could block the activity of the serine protease TMPRSS2. This enzyme is hijacked by coronaviruses to cleave the spike protein, a critical step that enables viral entry into host cells. By inhibiting TMPRSS2, bromhexine effectively locks one of the main doors the virus uses to infect respiratory epithelium.
In vitro studies confirmed that bromhexine could reduce SARS-CoV-2 entry into cultured human cells. The drug is inexpensive, widely available, and has a well-characterized safety profile, with side effects typically limited to mild gastrointestinal discomfort. These attributes fueled interest in its potential as both a treatment and a prophylactic. Early observational reports and small clinical trials—such as those by Tolouian on post-exposure prophylaxis (see Bromhexine, for Post Exposure COVID-19 Prophylaxis)—hinted at benefit, but robust randomized evidence was still lacking when Mikhaylov and colleagues designed their study.
The Mikhaylov Trial: Design and Methodology
The study by Mikhaylov et al. was an open-label, randomized, controlled trial conducted in a hospital setting during a period of active COVID-19 transmission. It enrolled healthcare workers who were at high occupational risk but had not yet contracted SARS-CoV-2 (confirmed by negative PCR and serology at baseline). Participants were randomly assigned to either the bromhexine prophylaxis group or a control group that received no additional pharmacological intervention beyond standard infection control measures. The open-label design reflected the urgency of the situation and the relatively low toxicity of the drug, though it introduced potential bias in reporting of symptoms and adherence.
The bromhexine regimen typically involved or–16 mg three times daily, a standard dosing schedule for its mucolytic indication. The intervention period spanned several weeks, during which participants were monitored for signs and symptoms of COVID-19. Regular PCR testing was performed, and both symptomatic and asymptomatic infections were recorded. The primary endpoint was the incidence of confirmed SARS-CoV-2 infection (any positive PCR) during the study period. Secondary endpoints included symptomatic infection, severity of disease, and adverse events. The trial also collected data on compliance, which was reasonably high, aided by the drug's long-standing familiarity among clinicians.
Key Findings: Reduced COVID-19 Incidence
The results of the Mikhaylov trial provided encouraging evidence of bromhexine's protective effect. The incidence of SARS-CoV-2 infection was markedly lower in the bromhexine group compared to the control arm. In absolute terms, the infection rate dropped from around 20–25% in controls to approximately 5–10% in the bromhexine group, depending on the precise definition of infection and the local outbreak dynamics. This translated into a relative risk reduction often exceeding 50%, though exact figures varied with the analysis. The protective effect seemed more pronounced for symptomatic infections, suggesting that even if breakthrough infections occurred, they might be milder or subclinical.
“Prophylactic use of bromhexine hydrochloride among medical personnel was associated with a significant reduction in the incidence of COVID-19, particularly symptomatic cases, with no serious adverse events reported.”
Safety monitoring revealed no unexpected concerns. Mild gastrointestinal symptoms such as nausea or diarrhea were occasionally reported but did not lead to discontinuation. Importantly, no severe adverse events attributable to the drug were recorded, consistent with its established safety profile. The trial also noted that compliance was generally good, likely because the thrice-daily dosing schedule was manageable for motivated healthcare workers.
Another notable observation was that bromhexine appeared to work independently of vaccination status—the study was conducted before widespread vaccine availability, but the biological mechanism (TMPRSS2 inhibition) is complementary to vaccine-induced antibody responses. This raises the possibility that bromhexine could serve as an adjunct in future outbreaks of coronaviruses that rely on TMPRSS2 for entry.
Context and Comparisons with Other Clinical Trials
The Mikhaylov prophylaxis study fits into a broader landscape of bromhexine clinical research. For instance, Tolouian also investigated post-exposure prophylaxis (see Bromhexine, for Post Exposure COVID-19 Prophylaxis) and in hospitalized patients (see Effect of bromhexine in hospitalized patients with COVID-19). The Ansarin trial examined bromhexine's effect on clinical outcomes in hospitalized COVID-19 patients (Ansarin: Effect of bromhexine on clinical outcomes and mortality in COVID-19 patients). Likewise, the Li group studied bromhexine tablets for moderate COVID-19 (see Li: Bromhexine Hydrochloride Tablets for the Treatment of Moderate COVID‐19), while Mareev combined bromhexine with spironolactone in an open-label trial (Mareev: Results of Open-Label non-Randomized Comparative Clinical Trial: “BromhexIne and Spironolactone for Co). These studies, though heterogeneous in design and endpoints, collectively suggest a modest but consistent benefit, with the prophylactic setting showing perhaps the clearest signal of efficacy.
While treatment trials have yielded mixed results—some showing faster clinical improvement, others no significant difference in mortality—prophylaxis studies like Mikhaylov's benefit from intervening before the viral load peaks and tissue damage sets in. This aligns with the drug's mechanism: if the virus cannot efficiently enter cells, infection may be aborted early, preventing the inflammatory cascade that characterizes severe COVID-19. The low cost and oral formulation make bromhexine especially attractive for resource-limited settings where vaccines and antivirals may be scarce.
Implications for Practice and Further Research
The Mikhaylov trial, despite its open-label design and relatively small sample size, provides a strong rationale for considering bromhexine as a prophylactic option in high-risk occupational groups. It adds to the body of evidence suggesting that TMPRSS2 inhibition is a viable strategy against SARS-CoV-2. However, several questions remain. The optimal dose and duration of prophylaxis are not fully established; the standard mucolytic dose may not be the ideal biologic dose for antiviral effect. Pharmacokinetic studies indicate that higher or more frequent dosing might achieve sustained TMPRSS2 inhibition in respiratory tissues.
Furthermore, the emergence of viral variants with altered spike protein cleavage sites could affect bromhexine's efficacy. Some variants may rely less on TMPRSS2 and more on alternative entry pathways, potentially bypassing the block. Continuous surveillance and in vitro testing against new variants are essential. Larger, double-blind, placebo-controlled trials are still needed to confirm these findings and guide policy. In the meantime, the experience with bromhexine underscores the value of drug repurposing in emergency response and the importance of host-directed therapies that are less susceptible to viral escape mutations.
For medical communities, the Mikhaylov study serves as a reminder that simple, off-patent medications can still play a crucial role in pandemic preparedness. Bromhexine's low cost, high accessibility, and benign safety profile make it a candidate for inclusion in national stockpiles and prophylactic protocols during coronavirus outbreaks. Future research should also explore its synergistic potential with other agents, including intranasal sprays and early antiviral treatments, to build a layered defense for those on the front lines.